One possible mechanism of protection from pneumococcal disease with a killed whole cell vaccine is by altering the carriage of pneumococcus germs in the nose and throat of those who get the vaccine. This study will look at nasal swabs from toddlers who received a killed whole cell pneumococcal vaccine (PATH-wSP) in VAC-010 and compare them to nasal swabs from toddlers of the same age who did not receive the PATH-wSP vaccine. This information will be used to help further develop the PATH-wSP vaccine. The research will be done in Kenya at one site in Kisumu (KEMRI). The study will enroll healthy Kenyan toddlers (12-15 months of age) who are participating in the VAC-010 study (N=250) and whose parents provide consent for this study. In addition 50 healthy Kenyan toddlers of similar age who did not participate in the VAC-010 study will also be enrolled.